Tumor markers for early detection of ovarian cancer

References

• Bertone-Johnson ER. Epidemiology of ovarian cancer: a status report. Lancet365, 101–102 (2005).
   PubMed Web of Science ®Google Scholar
• Ye B, Gagnon A, Mok SC. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev. Proteomics4(1), 121–131 (2007).
   PubMed Web of Science ®Google Scholar
• Ebert MP, Korc M, Malfertheiner P et al. Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J. Proteome Res.5, 19–25 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet353(9160), 1207–1210 (1999).
   PubMed Web of Science ®Google Scholar
• Nossov V, Amneus M, Su F et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am. J. Obstet. Gynecol.199(3), 215–223 (2008).
   PubMed Web of Science ®Google Scholar
• Abstracts of the first scientific workshop of the Early Detection Research Network. Dis. Markers17(1), 3–38 (2001).
   PubMedGoogle Scholar
• Kabawat SE, Bast RC Jr, Bhan AK et al. Tissue distribution of a coelomic–epithelium-related antigen recognized by the monoclonal antibody OC125. Int. J. Gynecol. Pathol.2(3), 275–85 (1983).
   PubMed Web of Science ®Google Scholar
• Bast RC Jr. Status of tumor markers in ovarian screening. J. Clin. Oncol.21(10), 200s–205s (2003).
   PubMedGoogle Scholar
• Duffy MJ, Bonfrer JM, Kulpa J et al. CA125 in ovarian cancer: European Group on tumor markers guidelines for clinical use. Int. J. Gynecol. Cancer15, 679–691 (2005).
   PubMed Web of Science ®Google Scholar
• Medeiros L, Rosa D, da Rosa M et al. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol.142(2), 99–105 (2009).
   PubMed Web of Science ®Google Scholar
• Skates SJ, Menon U, MacDonald N et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J. Clin. Oncol.21(10 Suppl.), 206–210 (2003).
   PubMedGoogle Scholar
• Menon U, Skates SJ, Lewis S et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol.23(31), 7919–7926 (2005).
   PubMed Web of Science ®Google Scholar
• Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol.10(4), 327–340 (2009).
   PubMed Web of Science ®Google Scholar
• Partridge E, Kreimer AR, Greenlee RT et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol.113(4), 775–782(2009).
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Carpi A et al. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed. Pharmacother.58(1), 24–38 (2004).
   PubMed Web of Science ®Google Scholar
• Koprowski H, Steplesky Z, Mitchell K et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet.5, 957–72 (1979)
   PubMedGoogle Scholar
• Gadducci A, Ferdeghini M, Prontera C et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol. Oncol.44(2), 147–154 (1992).
   PubMed Web of Science ®Google Scholar
• Skates SJ, Horick N, Yu Y et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15–13, CA 72–74, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol.22(20), 4059–4066 (2004).
   PubMed Web of Science ®Google Scholar
• Xu FJ, Yu YH, Daly L et al. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J. Clin. Oncol.11(8), 1506–1510 (1993).
   PubMed Web of Science ®Google Scholar
• Woolas RP, Conaway MR, Xu F et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol. Oncol.59(1), 111–116 (1995).
   PubMed Web of Science ®Google Scholar
• van Haaften-Day C, Shen Y, Xu F et al. OVX1, Macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. Cancer92(11), 2837–2844 (2001).
   PubMed Web of Science ®Google Scholar
• Xu Y, Fang XJ, Casey G et al. Lysophospholipids activate ovarian and breast cancer cells. Biochem. J.309(3), 933–940 (1995).
   PubMed Web of Science ®Google Scholar
• Xu Y, Shen Z, Wiper DW et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA280(8), 719–723 (1998).
   PubMed Web of Science ®Google Scholar
• Sutphen R, Xu Y, Wilbanks GD et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev.13(7), 1185–1191 (2004).
   PubMed Web of Science ®Google Scholar
• Sedláková I, Vávrová J, Tosner J et al. Lysophosphatidic acid: an ovarian cancer marker. Eur. J. Gynaecol. Oncol.29(5), 511–514 (2008).
   PubMedGoogle Scholar
• Tchagang AB, Tewfik AH, DeRycke MS et al. Early detection of ovarian cancer using group biomarkers. Mol. Cancer Ther.7(1), 27–37 (2008).
   PubMedGoogle Scholar
• Gorelik E, Landsittel DP, Marrangoni AM et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev.14(4), 981–987 (2005).
   PubMed Web of Science ®Google Scholar
• Lokshin AE, Winans M, Landsittel D et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol. Oncol.102(2), 244–251 (2006).
   PubMed Web of Science ®Google Scholar
• Oehler MK, Caffier H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res.20, 5109–5112 (2000).
   PubMed Web of Science ®Google Scholar
• Cooper BC, Ritchie JM, Broghammer CL et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res.8, 3193–3197 (2002).
   PubMed Web of Science ®Google Scholar
• Peng XP, Li JD, Li MD et al. Clinical significance of vascular endothelial growth factor in sera of patients with gynaecologicant malignant tumors. Ai Zheng.21, 181–185 (2002).
   PubMedGoogle Scholar
• Rosen DG, Wang L, Atkinson JN et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol.99(2), 267–277 (2005).
   Google Scholar
• Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod.1991, 45(2), 350–357 (1991).
   Google Scholar
• Moore RG, MacLaughlan S, Bast RC. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol. Oncol.116(2), 240–245 (2010).
   PubMedGoogle Scholar
• Hough CD, Sherman-Baust CA, Pizer ES et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res.60(22), 6281–6287 (2000).
   PubMed Web of Science ®Google Scholar
• Ono K, Tanaka T, Tsunoda T et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res.60(18), 5007–5011 (2000).
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Raycraft J, Hayden-Ledbetter M et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res.63(13), 3695–3700 (2003).
   PubMed Web of Science ®Google Scholar
• Rapkiewicz AV, Espina V, Petricoin EF 3rd et al. Biomarkers of ovarian tumours. Eur. J. Cancer.40(17), 2604–2612 (2004).
   PubMed Web of Science ®Google Scholar
• Lu KH, Patterson AP, Wang L et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res.10(10), 3291–3300 (2004).
   PubMed Web of Science ®Google Scholar
• Visintin I, Feng Z, Longton G et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res.14(4), 1065–1072 (2008).
   PubMed Web of Science ®Google Scholar
• Scholler N, Crawford M, Sato A et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin. Cancer Res.12(7 Pt 1), 2117–2124 (2006).
   PubMed Web of Science ®Google Scholar
• Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol.112(1), 40–46 (2009).
   PubMed Web of Science ®Google Scholar
• Moore RG, Brown AK, Miller MC et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol.108(2), 402–408 (2008).
   PubMed Web of Science ®Google Scholar
• Mok SC, Chao J, Skates S et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl Cancer Inst.93(19), 1458–1464 (2001).
   PubMed Web of Science ®Google Scholar
• Costa FP, Batista JEL, Zelmanowicz A et al. Prostatin, a potential tumor marker in ovarian cancer – a pilot study. Clinics64(7), 641–644 (2009).
   PubMedGoogle Scholar
• Takahashi S, Suzuki S, Inaguma S, Ikeda Y, Cho YM, Hayashi N. Down-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers. Prostate54, 187–193 (2003).
   PubMedGoogle Scholar
• Chen M, Chen LM, Lin CY, Chai KX. The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells. Biochim. Biophys. Acta.1783, 896–903 (2008).
   PubMed Web of Science ®Google Scholar
• Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques30(3), 670–675 (2001).
   PubMed Web of Science ®Google Scholar
• Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA287(13), 1671–1679 (2002).
   PubMed Web of Science ®Google Scholar
• Scholler N, Fu N, Yang Y et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl Acad. Sci. USA96(20), 11531–11536 (1999).
   PubMed Web of Science ®Google Scholar
• McIntosh MW, Drescher C, Karlan B et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol.95(1), 9–15 (2004).
   PubMed Web of Science ®Google Scholar
• Shah CA, Lowe KA, Paley P et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol. Biomarkers Prev.18(5), 1365–1372 (2009).
   PubMed Web of Science ®Google Scholar
• Badgwell D, Lu Z, Cole L et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free β subunit and urinary hCG β core fragment. Gynecol. Oncol.106(3), 490–497 (2007).
   PubMed Web of Science ®Google Scholar
• Yousef GM, Diamandis EP. Tissue kallikreins: new players in normal and abnormal cell growth? Thromb. Haemost.90(1), 7–16 (2003).
   PubMed Web of Science ®Google Scholar
• Yousef GM, Polymeris ME, Yacoub GM et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res.63(9), 2223–2227 (2003).
   PubMed Web of Science ®Google Scholar
• Shvartsman HS, Lu KH, Lee J et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol. Oncol.90(1), 44–50 (2003).
   PubMed Web of Science ®Google Scholar
• Adib TR, Henderson S, Perrett C et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br. J. Cancer.90, 686–692 (2004).
   PubMed Web of Science ®Google Scholar
• Simon I, Zhuo S, Corral L et al. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res.66, 1570–1575 (2006).
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res.67(18), 8699–8707 (2007).
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Urban N, Shridhar V et al. Early detection of ovarian cancer: promise and reality. In: Ovarian Cancer. Stack MS, Fishman DA (Eds). Kluwer, Boston, MA, USA 61–97 (2002).
   Google Scholar
• Zhang Z, Yu Y, Xu F et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol. Oncol.107(3), 526–531 (2007).
   PubMed Web of Science ®Google Scholar
• Nakae M, Iwamoto I, Fujino T et al. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J. Obstet. Gynaecol. Res.32(3), 309–314 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res.64(16), 5882–5890 (2004).
   PubMed Web of Science ®Google Scholar
• Nosov V, Su F, Amneus M et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am. J. Obstet. Gynecol.200(6), 639–641 (2009).
   PubMedGoogle Scholar
• Mor G, Visintin I, Lai Y et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl Acad. Sci.102, 7677–7682 (2005).
   PubMed Web of Science ®Google Scholar
• Ardekani AM, Akhondi MM, Sadeghi MR. Application of genomic and proteomic technologies to early detection of cancer. Arch. Iran. Med.11(4), 427–434 (2008).
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet359(9306), 572–577(2002).
   PubMed Web of Science ®Google Scholar
• Kong F, Nicole White C, Xiao X et al. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol. Oncol.100(2), 247–253 (2006).
   PubMedGoogle Scholar
• Kozak KR, Su F, Whitelegge JP et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics5(17), 4589–4596 (2005).
   PubMed Web of Science ®Google Scholar
• Lin YW, Lin CY, Lai HC et al. Plasma proteomic pattern as biomarkers for ovarian cancer. Int. J. Gynecol. Cancer16(1), 139–146 (2006).
   PubMedGoogle Scholar
• Ye B, Skates S, Mok SC et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res.12(2), 432–441 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang H, Kong B, Qu X et al. Biomarker discovery for ovarian cancer using SELDI-TOFMS. Gynecol. Oncol.102(1), 61–66 (2006).
   PubMed Web of Science ®Google Scholar
• Faca VM, Ventura AP, Fitzgibbon MP et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extracellular domains. PLoS ONE3(6), e2425 (2008).
   PubMedGoogle Scholar
• Pitteri SJ, JeBailey L, Fac¸a VM et al. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS ONE4(11), e7916 (2009).
   PubMed Web of Science ®Google Scholar
• Gortzak-Uzan L, Ignatchenko A, Evangelou AI et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J. Proteome Res.7(1), 339–351 (2008).
   PubMed Web of Science ®Google Scholar
• Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell Proteomics3, 1154–1169 (2004).
   PubMed Web of Science ®Google Scholar
• Gagné JP, Éthier C, Gagné P et al. Comparative proteome analysis of human epithelial ovarian cancer. Proteome Sci.5, 16 (2007).
   PubMedGoogle Scholar
• Kothandaraman N, Zhao CQ, Mahesh C. Ovarian cancer proteomics: many technologies one goal. Proteomics Clin. Appl.2(2), 195–218 (2008).
   PubMedGoogle Scholar
• Denkert C, Budczies J, Kind T et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res.66, 10795–10804 (2006).
   PubMed Web of Science ®Google Scholar
• Nelson A, Francis JE, Zorbas H. Population screening and early detection of ovarian cancer in asymptomatic women. Aust. NZ J. Obstet. Gynaecol.49, 448–450 (2009).
   PubMedGoogle Scholar
• Anderson GL, McIntosh M, Wu Ll et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case–control study. J. Natl Cancer Inst.102, 26–38 (2010).
   PubMed Web of Science ®Google Scholar
• Williams TI, Toups KL, Saggese DA., Kalli KR, Cliby WA, Muddiman DC. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J. Proteome Res.6, 2936–2962 (2007).
   PubMedGoogle Scholar
• Sjovall K, Nilsson B, Einhorn N et al. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol. Oncol.85(1), 175–178 (2002).
   PubMed Web of Science ®Google Scholar
• Buys SS, Partridge E, Greene MH et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am. J. Obstet. Gynecol.193(5), 1630–1639 (2005)
   PubMed Web of Science ®Google Scholar
• Meinhold-Heerlein I, Brautigam K, Bauerschlag DO et al. Serum biomarkers for early detection of ovarian cancer. Geburtshilfe Frauenheilkd68(8), 830–837 (2008).
   Google Scholar
• Kim K, Visintin I, Alvero AB et al. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin. Lab. Med.29(1), 47–55 (2009).
   PubMed Web of Science ®Google Scholar
• Rai AJ, Zhang Z, Rosenzweig J et al. Proteomic approaches to tumor marker discovery – identification of biomarkers for ovarian cancer. Arch. Pathol. Lab. Med.126(12), 1518–1526 (2002).
   PubMed Web of Science ®Google Scholar
• Ye B, Cramer DW, Skates SJ et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res.9(8), 2904–2911 (2003).
   PubMed Web of Science ®Google Scholar
• Vlahou A, Schorge JO, Gregory BW et al. Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J. Biomed. Biotechnol.5, 308–314 (2003).
   Google Scholar
• Liu CW, Shea N, Rucker S et al. Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. Proteomics7(22), 4045–4052 (2007).
   PubMedGoogle Scholar
• Assareh A, Moradi MH. Extracting efficient fuzzy if-then rules from mass spectra of blood samples to early diagnosis of ovarian cancer. Proceedings of the 2007 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology 502–506 (2007).
   Google Scholar
• Lopez MF, Mikulskis A, Kuzdzal S et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem.53(6), 1067–1074 (2007).
   PubMed Web of Science ®Google Scholar